Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?

Autor: Ladekarl, Morten

Publikováno v: Ladekarl, M 2023, ' Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit? ', Chinese clinical oncology, vol. 12, no. 2, 10, pp. 10 . https://doi.org/10.21037/cco-23-17

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de23b28cc5d0be3910845491adf236ff
https://vbn.aau.dk/ws/files/526457092/Ladekarl_2023_._Pembrolizumab_for_second_line_treatment_of_advanced_hepatocellular_carcinoma_who_would_benefit.pdf

Hepatocellular Carcinoma Treatment With Sorafenib: Real-Life Evaluation of Prognostic Factors and a Practical Clue for Patient Management

Autor: Helder Cardoso, Ana Margarida Alves, Margarida Marques, Ana Maria Vale, Pedro Pereira, Guilherme Macedo

Publikováno v: GE: Portuguese Journal of Gastroenterology, Vol 23, Iss 5, Pp 243-248 (2016)

Introduction: Sorafenib chemotherapy is the first-line therapy for patients with hepatocellular carcinoma (HCC) in an advanced stage. The aim of this study was to evaluate prognostic factors of survival in HCC patients treated with sorafenib, in real

Externí odkaz: https://doaj.org/article/8af497d685fd4275a89eae4a30ec6740

Liver stiffness improvement in hepatitis C patients after successful treatment

Publikováno v: Netherlands journal of medicine. 78(6):368-375

BACKGROUND: Successful treatment of chronic hepatitis C with direct-acting antiviral agents (DAAs) is expected to lead to improvement in liver fibrosis in most of the patients. However, limited data are available on the improvement of advanced liver

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::66f9e52067b4ae509df1313b875c8379

Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin

Autor: Tsinat Berhane, Anja Holm, Kasper Thystrup Karstensen, Andreas Petri, Mirolyuba Simeonova Ilieva, Henrik Krarup, Mogens Vyberg, Marianne Bengtson Løvendorf, Sakari Kauppinen

Publikováno v: Berhane, T, Holm, A, Karstensen, K T, Petri, A, Ilieva, M S, Krarup, H, Vyberg, M, Løvendorf, M B & Kauppinen, S 2022, ' Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin ', Scientific Reports, vol. 12, no. 1, 19502 . https://doi.org/10.1038/s41598-022-23802-9
Berhane, T, Holm, A, Karstensen, K T, Petri, A, Ilieva, M S, Krarup, H, Vyberg, M, Løvendorf, M B & Kauppinen, S 2022, ' Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin ', Scientific Reports, vol. 12, 19502 . https://doi.org/10.1038/s41598-022-23802-9

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with increasing incidence in western countries. Most HCC patients have advanced cancer at the time of diagnosis due to the asymptomatic nature of early-stage HCC and do no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aec59f073855c358533957039449abe8
https://pubmed.ncbi.nlm.nih.gov/36376362

MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective

Autor: Fouad, Yasser, Lazarus, Jeffrey V, Negro, Francesco, Peck-Radosavljevic, Markus, Sarin, Shiv K, Ferenci, Peter, Esmat, Gamal, Ghazinian, Hasmik, Nakajima, Atsushi, Silva, Marcelo, Lee, Samuel, Colombo, Massimo

Publikováno v: Alimentary Pharmacology and Therapeutics, Vol. 53, No 10 (2021) pp. 1080-1089

The World Health Organization (WHO) set a goal to eliminate hepatitis C (HCV) infection globally by 2030, with specific targets to reduce new viral hepatitis infections by 80% and reduce related deaths by 65%. However, an overlooked aspect that may h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1400::f17c623989ebafe741bb79b6c7bd2e7a
https://archive-ouverte.unige.ch/unige:152677